|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| PharmaVitae 2005 :Merger Analysis Tool |
|
|
|
|
€ 24 320,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2005 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
2 835,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
Healthcare: Germany
106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the |
578,54 €
|
| |
| |
The CNS Outlook 1998-2010
201 pages | Août 1999 |
In 1998, the CNS market expanded by 12.8%, growing in value from $29.4bn in 1997 to almost $33bn in 1998.
Expansion is being driven by the introduction of new technologies and products which are ra |
795,00 €
|
| |
| |
The Cardiovascular Outlook 1998-2010
186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998.
Market expansion is being driven by expanding prevalent populations in t |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| PharmaVitae 2005 :Merger Analysis Tool |
|
|
Introduction
The Merger Analysis Tool models potential outcome of a merger between any two of the 50 companies tracked by PharmaVitae. Users can retain or divest specific products, rationalize forecasts to account for impact of a merger, analyze the resulting company by forecast therapeutic and strategic measures, and compare the merged company with its pre-merger partners or any of the 50 tracked companies.
Reasons to Purchase
Model merged portfolios at the drug level, to establish the commercial potential and viability of the merged portfolios and development pipelines
Compare a virtual company directly with its pre-merger partners, to provide strategic insight into the potential of the prospectively-merged company
Decide which products to retain or divest, then forecast ethical sales by drug and therapy area to 2010 for the virtual merged company
|
|
|
PPLSEN
|
|
|
|
|
